S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
S&P 500   3,934.38
DOW   33,476.46
QQQ   282.04
Retirement Doesn't Have to Mean Golf Courses and Fishing — It Can Be Whatever You Want It to Be.
Why Your IRA Could Crash on January 16th? (Ad)
Can Pfizer, Johnson & Johnson Continue Outperforming the Index?
Costco vs Amazon: an end of the year showdown
The 3-Stock Retirement Blueprint (Ad)
There Is Fundamental Value In Broadcom, And It Yields 3.35% 
Closing prices for crude oil, gold and other commodities
The 3-Stock Retirement Blueprint (Ad)
Discount Retailers Could Make Good Bargain Stocks
How major US stock indexes fared Friday 12/9/2022
OTCMKTS:REVB

Revelation Biosciences - REVB Stock Forecast, Price & News

$0.20
0.00 (0.00%)
(As of 12/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.20
▼
$0.22
50-Day Range
$0.20
▼
$0.41
52-Week Range
$0.19
▼
$11.29
Volume
223,367 shs
Average Volume
2.61 million shs
Market Capitalization
$4.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Revelation Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
6,022.4% Upside
$12.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.66) to ($0.37) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

See Top Rated MarketRank™ Stocks Here
REVB stock logo

About Revelation Biosciences (OTCMKTS:REVB) Stock

Revelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-100, a potential therapy for the prevention and treatment of healthcare-associated bacterial infection resulting from surgery, severe burns, and antibiotic resistance; REVTx-200, a potential intranasal therapy; and REVTx-300, a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis. It is also developing REVTx-99b, a treatment for food allergies; REVTx-99a, an anti-viral nasal drop solution for the potential prevention or treatment of respiratory viral infection; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, influenza A, influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.

Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

REVB Stock News Headlines

December 6, 2022 | americanbankingnews.com
Reviewing Savara (NASDAQ:SVRA) and Revelation Biosciences (OTCMKTS:REVB)
November 18, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model
November 10, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2022 and Recent Corporate Progress
October 25, 2022 | finance.yahoo.com
Revelation Biosciences Stock Soars After Encouraging Preclinical Data From Kidney Disease Candidate
October 25, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease
October 6, 2022 | msn.com
Why Revelation Biosciences Stock Is Popping Off
October 6, 2022 | finance.yahoo.com
Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement
September 18, 2022 | investing.com
Revelation Biosciences Inc Unit (REVBU)
September 1, 2022 | nasdaq.com
One Revelation Biosciences, Inc. (NASDAQ:REVB) insider upped their stake by 2.8% in the previous year
September 1, 2022 | uk.finance.yahoo.com
Revelation Biosciences, Inc. (REVB)
August 31, 2022 | finance.yahoo.com
Bears are Losing Control Over Revelation Biosciences, Inc. (REVB), Here's Why It's a 'Buy' Now
August 31, 2022 | uk.finance.yahoo.com
A Revelation Biosciences, Inc. (NASDAQ:REVB) insider increased their holdings by 2.8% last year
August 17, 2022 | seekingalpha.com
Revelation Biosciences GAAP EPS of -$0.12
August 16, 2022 | tmcnet.com
Revelation Biosciences Inc. Announces Financial Results for the
August 16, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2022 and Recent Corporate Progress
July 29, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Closing of $5 Million Public Offering
July 26, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Pricing of $5 Million Public Offering
July 25, 2022 | finance.yahoo.com
Revelation Biosciences Surges After Encouraging Data From Allergic Rhinitis Study
July 22, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Topline Data for Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
July 14, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Completes Database Lock for its Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
June 13, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Completion of Dosing for a Phase 1b CLEAR Clinical Study of REVTx-99b for the Treatment of Allergic Rhinitis
May 23, 2022 | seekingalpha.com
Safety committee recommends continuing Revelation's phase 1b trial for hay fever treatment
May 23, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Safety Monitoring Committee Recommendation for Continuing Evaluation of REVTx-99b for the Treatment of Allergic Rhinitis
May 16, 2022 | seekingalpha.com
Revelation Biosciences GAAP EPS of -$0.47
May 16, 2022 | finance.yahoo.com
Revelation Biosciences Inc. Announces Financial Results for the Three Months Ended March 31, 2022 and Recent Corporate Progress
See More Headlines
Receive REVB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Revelation Biosciences and its competitors with MarketBeat's FREE daily newsletter.

REVB Company Calendar

Last Earnings
11/10/2022
Today
12/09/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:REVB
CUSIP
N/A
CIK
1810560
Web
www.revbiosciences.com
Phone
971-622-5800
Fax
N/A
Employees
2
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+6,022.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-2,130,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
-21.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.49
Quick Ratio
1.49

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.30) per share
Price / Book
-0.05

Miscellaneous

Outstanding Shares
23,536,000
Free Float
18,852,000
Market Cap
$4.61 million
Optionable
Not Optionable
Beta
-0.35

Key Executives

  • Mr. James M. Rolke (Age 53)
    CEO & Director
    Comp: $466.63k
  • Mr. Chester Stanley Zygmont III (Age 42)
    Chief Financial Officer
    Comp: $366.64k
  • Ms. Sandra Vedrick
    VP of HR & Investor Relations
  • Ms. Carol Odle
    Sr. Director of Clinical Projects

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













REVB Stock - Frequently Asked Questions

Should I buy or sell Revelation Biosciences stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Revelation Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" REVB shares.
View REVB analyst ratings or view top-rated stocks.

What is Revelation Biosciences' stock price forecast for 2023?

1 Wall Street analysts have issued 1 year price targets for Revelation Biosciences' stock. Their REVB share price forecasts range from $12.00 to $12.00. On average, they expect the company's stock price to reach $12.00 in the next year. This suggests a possible upside of 6,022.4% from the stock's current price.
View analysts price targets for REVB or view top-rated stocks among Wall Street analysts.

How have REVB shares performed in 2022?

Revelation Biosciences' stock was trading at $22.52 at the start of the year. Since then, REVB shares have decreased by 99.1% and is now trading at $0.1960.
View the best growth stocks for 2022 here.

How were Revelation Biosciences' earnings last quarter?

Revelation Biosciences, Inc. (OTCMKTS:REVB) announced its quarterly earnings results on Thursday, November, 10th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.03.

What other stocks do shareholders of Revelation Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Revelation Biosciences investors own include Primo Water (PRMW), Almaden Minerals (AAU), AA (AATDF), American Assets Trust (AAT), Advance Auto Parts (AAP), AAON (AAON), Applied Optoelectronics (AAOI), Aaron's (AAN), American Airlines Group (AAL) and AAC Technologies (AACAY).

What is Revelation Biosciences' stock symbol?

Revelation Biosciences trades on the OTCMKTS under the ticker symbol "REVB."

Who are Revelation Biosciences' major shareholders?

Revelation Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include State Street Corp (0.46%).
View institutional ownership trends.

How do I buy shares of Revelation Biosciences?

Shares of REVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Revelation Biosciences' stock price today?

One share of REVB stock can currently be purchased for approximately $0.20.

How much money does Revelation Biosciences make?

Revelation Biosciences (OTCMKTS:REVB) has a market capitalization of $4.61 million.

How can I contact Revelation Biosciences?

The official website for the company is www.revbiosciences.com. The company can be reached via phone at 971-622-5800 or via email at svedrick@revbiosciences.com.

This page (OTCMKTS:REVB) was last updated on 12/10/2022 by MarketBeat.com Staff